Trifecta Valve: An Evidence-Based Patient Guide

The Trifecta valve is a bovine tissue valve used during surgical aortic valve replacement. It is a stented bioprosthetic valve, and patients who have one should continue regular heart follow-up because reports of earlier-than-expected structural valve deterioration led to its market withdrawal in the United States.

Overview: What Is the Trifecta Valve?

The Trifecta valve is a surgical biological, or tissue, valve designed to replace a narrowed or leaking aortic valve. It is made from bovine (cow) pericardial tissue mounted on a supporting frame. Surgeons implant it during surgical aortic valve replacement (SAVR), an operation that removes the diseased aortic valve and sews a replacement valve into place.

In 2023, the manufacturer stopped selling and distributing Trifecta and Trifecta GT valves in the United States after safety concerns about structural valve deterioration. This does not mean that a person with an implanted Trifecta valve needs emergency treatment or automatic replacement. It does mean regular review with a cardiologist is important, including echocardiography to assess how the valve is functioning.

Aortic valve disease can develop from calcific aortic stenosis, congenital valve differences or valve leakage. The best treatment is individualized and may include monitoring, surgery or transcatheter therapy. Decisions are usually made with a heart team that includes cardiologists, cardiac surgeons, imaging specialists and other relevant clinicians.

How the Trifecta Valve Works and Why Monitoring Matters

A healthy aortic valve opens to let blood leave the heart and closes to prevent blood from flowing backward. A replacement tissue valve is intended to restore one-way blood flow. The Trifecta design places the tissue leaflets on the outside of its frame, which may provide favorable blood-flow characteristics immediately after implantation in some patients.

Like all biological valves, Trifecta valves can gradually wear over time. This is called structural valve deterioration. The valve leaflets may become stiff, torn, calcified or less able to close, causing recurrent narrowing, leakage or both. The timing and severity vary substantially between individuals.

The term trifecta valve FDA commonly refers to the US Food and Drug Administration safety communication concerning a potential risk of early structural valve deterioration. The FDA advised healthcare professionals to discuss this risk, perform lifelong routine follow-up, and obtain an echocardiogram at least yearly after implantation or sooner if symptoms develop.

Routine follow-up is valuable even when a person feels well, because valve changes can sometimes be detected before they cause major symptoms. The cardiology team compares current scans with earlier echocardiograms, checks heart function, and considers symptoms, blood pressure and other heart conditions.

Is the Trifecta Valve Stented?

Yes. The Trifecta valve is a stented surgical bioprosthetic aortic valve. “Stented” means that the biological tissue is attached to a supporting frame that helps the valve retain its shape after it is sewn into the heart.

This differs from stentless surgical valves, which do not have a supporting frame, and from mechanical valves, which are made of durable synthetic materials. Mechanical valves generally require lifelong anticoagulant treatment, whereas tissue valves often do not require lifelong anticoagulation solely because of the valve. However, some people need blood-thinning medication for other reasons, such as atrial fibrillation.

Being stented does not by itself determine whether a valve will last longer or whether a future transcatheter procedure is possible. For patients with a failing surgical tissue valve, detailed CT and echocardiographic imaging helps the heart team assess options such as repeat surgery or a transcatheter valve placed inside the existing valve.

Trifecta Valve Recall, Symptoms and Potential Complications

People may describe the withdrawal as a trifecta valve recall, although it is important to distinguish a market withdrawal and safety communication from a directive that all implanted valves must be removed. An individual valve should be evaluated based on symptoms, examination findings and imaging results. Patients should not stop prescribed medicines or delay follow-up because of online information alone.

Possible symptoms of a deteriorating aortic valve can include increasing shortness of breath, reduced exercise tolerance, chest pressure, tiredness, ankle swelling, palpitations, dizziness or fainting. These symptoms can also result from other heart or lung conditions, so they need medical assessment rather than self-diagnosis.

Some valve problems are found on a routine echocardiogram before symptoms occur. If deterioration is suspected, clinicians may use transthoracic or transesophageal echocardiography, CT imaging, cardiac catheterization or other tests to clarify the severity, identify associated coronary disease, and plan treatment safely.

Potential complications of untreated severe valve dysfunction include heart failure, abnormal heart rhythms and reduced quality of life. Timely surveillance allows the team to discuss intervention before symptoms or heart changes become advanced, when appropriate.

Treatment Options: Repeat Surgery and Trifecta Valve-in-Valve TAVR

If a Trifecta valve is functioning normally, treatment is usually ongoing surveillance rather than an intervention. If the valve develops significant narrowing or leakage, the care team considers the person’s symptoms, heart function, valve measurements, medical conditions, prior procedures and preferences.

One option is repeat surgical aortic valve replacement. During this operation, the surgeon removes the failing valve and implants a new valve. Surgery may be preferred when there are other surgical needs, such as coronary bypass surgery, infection, aortic disease, or anatomy that is not suitable for a transcatheter approach.

Another option for selected patients is trifecta valve in valve TAVR, also called valve-in-valve transcatheter aortic valve replacement. A new transcatheter valve is delivered, usually through an artery in the groin, and expanded within the failing surgical valve. It can avoid repeat open-heart surgery, but it is not suitable for everyone. Small prior valve size, coronary artery anatomy, the risk of blocking coronary blood flow, and expected remaining gradients across the valve are especially important considerations.

Planning should take place at an experienced valve center, where cardiac imaging and both surgical and transcatheter expertise are available. Aortic valve replacement evaluation can help determine the most appropriate pathway for the individual patient.

Should a 78 Year Old Have TAVR or SAVR?

A 78-year-old may be a candidate for either TAVR or SAVR; there is no single answer based on age alone. TAVR is a less invasive catheter-based procedure and may support a shorter initial recovery for many suitable patients. SAVR remains an important option, particularly when anatomy, other heart problems or the need for a durable surgical solution favors surgery.

The heart team reviews overall fitness, frailty, kidney and lung function, life expectancy, the severity and type of valve disease, CT scan findings, artery access, coronary artery disease and personal priorities. A person who is physically active and has few other health concerns may make a different choice from someone with substantial medical complexity, even at the same age.

For a failing surgical tissue valve, the decision also includes whether valve-in-valve TAVR is technically safe and likely to provide good blood flow. Shared decision-making is essential: patients should understand the likely benefits, limitations, recovery needs and possible future treatment pathways of each option.

Acibadem International’s multidisciplinary specialists and JCI-accredited hospitals can assess aortic valve disease and discuss surgical and transcatheter treatment options for international patients.

What Is the Average Life Expectancy of an 80 Year Old After Aortic Valve Replacement?

There is no reliable single average life-expectancy figure for every 80-year-old after aortic valve replacement. Outcomes depend on the severity of valve disease before treatment, heart pumping function, frailty, kidney and lung health, coronary artery disease, complications, rehabilitation, and the person’s overall health and function.

For many older adults with severe symptomatic aortic stenosis, successful valve replacement can relieve symptoms and improve daily functioning. In appropriately selected patients, treatment may also improve survival compared with leaving severe symptomatic valve disease untreated. However, neither SAVR nor TAVR can remove risks related to other medical conditions or the normal effects of aging.

Clinicians often focus less on a single life-expectancy estimate and more on goals that matter to the individual: breathing more comfortably, walking farther, living independently, avoiding hospital admissions and returning to valued activities. A geriatric assessment may be helpful when frailty, memory concerns, nutrition or mobility affect treatment decisions.

After replacement, follow-up appointments, echocardiograms, cardiac rehabilitation when appropriate, medication review and attention to blood pressure, activity and dental health all support longer-term recovery.

Should a 90 Year Old Have Heart Valve Replacement? When to Seek Medical Care

A 90-year-old can be considered for heart valve replacement when severe valve disease is causing symptoms and treatment is expected to provide meaningful benefit. Age alone should not exclude a person from evaluation. At the same time, clinicians carefully consider frailty, independence, cognitive function, other serious illnesses, anatomy, procedural risks and the person’s wishes.

For some nonagenarians, TAVR may be a reasonable option because it is less invasive than open surgery. For others, a procedure may be unlikely to improve comfort, function or quality of life enough to outweigh its burdens. Supportive care and symptom-focused treatment are valid choices when they better match a person’s health status and goals.

Urgent medical assessment is needed for new or worsening breathlessness at rest, chest pain, fainting, rapidly increasing leg swelling, sudden confusion, or a marked decline in exercise tolerance. A person with a Trifecta valve should also contact their cardiology team promptly if familiar valve-related symptoms return or worsen.

Regular, non-urgent follow-up is appropriate for people who feel well but are due for valve surveillance. Bringing prior operative records and echocardiogram reports to appointments can help the team identify the valve model, size and changes over time.

Frequently asked questions

What is the Trifecta valve?

The Trifecta valve is a biological aortic valve replacement used in open-heart surgery. It uses bovine pericardial tissue supported by a frame and is designed to restore normal one-way blood flow from the heart to the body.

Why was the Trifecta valve withdrawn from the US market?

The manufacturer stopped US sales and distribution after reports of structural valve deterioration that could occur earlier than expected in some patients. The FDA issued communications advising lifelong routine follow-up for people who have these valves.

Does everyone with a Trifecta valve need another procedure?

No. A Trifecta valve withdrawal does not mean every implanted valve has failed or needs preventive replacement. Decisions depend on symptoms, echocardiogram findings, the degree of valve dysfunction and the person’s overall health.

Can a Trifecta valve be treated with TAVR?

Some failing Trifecta valves may be treated with valve-in-valve TAVR. Suitability depends on detailed imaging, the size of the previous valve, coronary artery position and other anatomical factors, so assessment by a structural heart team is necessary.

How often should a Trifecta valve be checked?

Patients should follow their cardiologist’s surveillance plan. FDA communications have advised at least yearly echocardiographic follow-up after implantation, with earlier testing if symptoms such as breathlessness, chest discomfort, fainting or reduced stamina occur.

Is a tissue valve better than a mechanical valve?

Neither option is universally better. Tissue valves usually avoid lifelong anticoagulation solely for the valve, while mechanical valves may have greater durability but require ongoing anticoagulant therapy. The best choice depends on age, health, preferences, bleeding risk and plans for future treatment.

References

• U.S. Food and Drug Administration
• American College of Cardiology
• American Heart Association
• European Society of Cardiology
• Society of Thoracic Surgeons

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.